Effect of Hibiscus subdariffa on albuminuria, total antioxidant capacity, hypertension and hs-CRP in patient with diabetic nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014041510826N8

Enrollment

Registered

2014-07-05

Start date

2014-04-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. Diabetic nephropathy

Interventions

Intervention 1: intervention group:take 2 hibiscus subdariffa tablet (425mg) dailys. Intervention 2: Control group:take 2 placebo tablet daily for2 months.

Treatment - Drugs

Placebo

intervention group:take 2 hibiscus subdariffa tablet (425mg) dailys

Control group:take 2 placebo tablet daily for2 months

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: micro and macro albuminuria(proteinuria more than 30 mg/24h; HbA1C18 years old. Exclusion criteria: patients without using 80 percent of hibiscus subdariffa supplements; patients who changed the type or the doses of their drugs and patients who changed their diet.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Kidney function. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: urine and blood test.;Albuninuria. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: urine test.;Total antioxidant cepacity. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: blood test.;Blood presure. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: manometer.;Hs-crp. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: blood test.	—

Measure

Time frame

Kidney function. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: urine and blood test.;Albuninuria. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: urine test.;Total antioxidant cepacity. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: blood test.;Blood presure. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: manometer.;Hs-crp. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: blood test.

—

Secondary

Measure	Time frame
BUN. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: Biochemical blood check.;Cr. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: Biochemical blood check.;BMI. Timepoint: before the intervention and 2 month following end of intervention. Method of measurement: Meter, scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Esmaeili

Shahid Sadoughi University of Medical Sciences

esmaeili.akram86@yahoo.com+98 31 4263 1721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026